Company Sees Q1 Adjusted EBITDA Loss of $4M-$5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy LFMD?
Sees Q1 adjusted EBITDA loss $4M-$5M. The company said, "Adjusted EBITDA expected to return to profitability in Q2 as customer acquisition costs decline sequentially and the substantial rise in patient volumes becomes accretive for the balance of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.120
Low
6.00
Averages
9.67
High
15.00
Current: 3.120
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LifeMD Stock Soars After Strong Q4 Performance and Upgraded Rating
- Stock Surge: LifeMD's stock soared by as much as 23.56% to $3.86 on Tuesday after Cantor Fitzgerald reiterated its Overweight rating, reflecting strong market confidence in the company's growth prospects.
- Performance Beat: The company reported a Q4 loss of $0.04 per share with revenue increasing by 3.9% to $46.87 million, both metrics exceeding analyst expectations, indicating the effectiveness of its business model.
- Cautious Guidance: Although Q1 revenue guidance of $48 million to $49 million fell short of the $49.33 million consensus, the full-year revenue forecast of $220 million to $230 million remains above market expectations.
- Profitability Outlook: LifeMD anticipates returning to profitability in Q2 as customer acquisition costs decline and patient volumes surge, projecting an annualized revenue run rate exceeding $250 million and adjusted EBITDA surpassing $25 million by Q4 2026.
See More
LifeMD Reports Strong Q4 and Full Year 2025 Earnings Growth
- Significant Revenue Growth: LifeMD reported Q4 2025 revenue of $46.9 million, a 4% year-over-year increase, with full-year revenue reaching $194.1 million, reflecting a robust 25% growth that underscores the company's strong market performance and growth potential.
- Margin Fluctuations: While the gross margin for Q4 2025 improved to 87.1%, an increase of 570 basis points year-over-year, the full-year gross margin slightly decreased to 85.7%, indicating challenges in cost management and profitability.
- Cash Flow and Subscriber Growth: By the end of 2025, LifeMD held $36.8 million in cash with no debt, and active subscribers approached 323,000, marking a 16% year-over-year increase, providing a solid financial foundation for future expansion and investments.
- Future Outlook and Challenges: The company anticipates Q1 2026 revenue between $48 million and $49 million, facing high customer acquisition costs and competitive pressures, yet continues to invest in marketing and AI technologies to enhance operational efficiency.
See More
LifeMD, Inc. Reports Strong Q4 2025 Earnings with Positive Outlook
- Significant User Growth: LifeMD ended Q4 2025 with over 322,000 active subscribers, onboarding approximately 1,200 new patients daily and attracting over 120,000 unique daily website visitors, indicating strong momentum in patient acquisition that is expected to drive revenue growth further.
- Strong Financial Performance: The company reported Q4 revenue of $46.9 million, a 4% increase year-over-year, with a gross margin of 87.1% and a net income of $19 million, reflecting significant improvements in cost control and profitability that bolster investor confidence.
- Deepening Strategic Partnerships: The successful launch of oral Wegovy in collaboration with Novo Nordisk positions LifeMD as one of the few virtual care providers fully integrated with major pharmaceutical companies, which is expected to further expand market share and enhance brand influence.
- Optimistic Future Outlook: Management anticipates Q1 2026 revenue in the range of $48 million to $49 million, with a full-year revenue target of $220 million to $230 million, demonstrating confidence in future growth while planning to return to adjusted EBITDA profitability in Q2.
See More
LifeMD Reports Q4 2025 Results Exceeding Expectations
- Strong Earnings Report: LifeMD reported Q4 2025 revenue of $46.9 million, exceeding market expectations by $1.29 million, showcasing the company's robust growth potential in the telehealth sector.
- Improved Profitability: The company achieved a year-over-year gross profit increase of approximately 11%, reaching $40.8 million, reflecting enhanced operational efficiency and cost control capabilities.
- Optimistic Future Outlook: LifeMD projects 2026 revenue between $220 million and $230 million, with a midpoint of $225 million, surpassing the consensus estimate of $222.64 million, indicating strong confidence in future growth.
- Debt-Free Advantage: As of the end of 2025, LifeMD has no debt, providing a solid financial foundation for future expansion and investments, thereby enhancing its competitive position in the market.
See More
LifeMD Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Highlights: LifeMD reported a Q4 GAAP EPS of -$0.04, beating expectations by $0.02, with revenue of $46.9 million reflecting a 3.9% year-over-year increase, surpassing estimates by $1.29 million, indicating robust market performance.
- Future Outlook: The guidance for Q1 2026 projects revenue between $48 million and $49 million, showcasing the company's confidence in future growth, particularly as GLP-1 patient sign-ups have doubled compared to Q4 2025.
- Adjusted EBITDA Expectations: Adjusted EBITDA is expected to return to profitability in Q2 2026 as customer acquisition costs decline, with a significant rise in patient volumes positively impacting the financial results for the latter half of 2026.
- Annual Guidance: For the full year 2026, revenue is projected between $220 million and $230 million, representing a year-over-year growth of 13% to 19%, with annualized run-rate revenue expected to exceed $250 million by Q4 2026, driven by momentum in GLP-1 and women's health sectors.
See More
LifeMD Executives Allegedly Breached Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether LifeMD, Inc. executives breached their fiduciary duties to shareholders, with potential legal risks that could undermine shareholder confidence.
- Overstated Competitive Position: A federal securities lawsuit claims that LifeMD's competitive position was materially overstated, which may distort investor expectations regarding the company's future and impact shareholder investment decisions.
- Improper Financial Guidance: LifeMD's decision to raise its 2025 guidance is criticized as reckless due to the failure to adequately account for rising customer acquisition costs in its RexMD segment, potentially leading to poor future financial performance.
- Lack of Disclosure: The company failed to disclose customer acquisition costs related to the sale of obesity drugs, resulting in materially false and misleading statements about LifeMD's business, operations, and prospects, which could trigger shareholder lawsuits.
See More
LifeMD Stock Soars After Strong Q4 Performance and Upgraded Rating
- Stock Surge: LifeMD's stock soared by as much as 23.56% to $3.86 on Tuesday after Cantor Fitzgerald reiterated its Overweight rating, reflecting strong market confidence in the company's growth prospects.
- Performance Beat: The company reported a Q4 loss of $0.04 per share with revenue increasing by 3.9% to $46.87 million, both metrics exceeding analyst expectations, indicating the effectiveness of its business model.
- Cautious Guidance: Although Q1 revenue guidance of $48 million to $49 million fell short of the $49.33 million consensus, the full-year revenue forecast of $220 million to $230 million remains above market expectations.
- Profitability Outlook: LifeMD anticipates returning to profitability in Q2 as customer acquisition costs decline and patient volumes surge, projecting an annualized revenue run rate exceeding $250 million and adjusted EBITDA surpassing $25 million by Q4 2026.
See More
LifeMD Reports Strong Q4 and Full Year 2025 Earnings Growth
- Significant Revenue Growth: LifeMD reported Q4 2025 revenue of $46.9 million, a 4% year-over-year increase, with full-year revenue reaching $194.1 million, reflecting a robust 25% growth that underscores the company's strong market performance and growth potential.
- Margin Fluctuations: While the gross margin for Q4 2025 improved to 87.1%, an increase of 570 basis points year-over-year, the full-year gross margin slightly decreased to 85.7%, indicating challenges in cost management and profitability.
- Cash Flow and Subscriber Growth: By the end of 2025, LifeMD held $36.8 million in cash with no debt, and active subscribers approached 323,000, marking a 16% year-over-year increase, providing a solid financial foundation for future expansion and investments.
- Future Outlook and Challenges: The company anticipates Q1 2026 revenue between $48 million and $49 million, facing high customer acquisition costs and competitive pressures, yet continues to invest in marketing and AI technologies to enhance operational efficiency.
See More
LifeMD, Inc. Reports Strong Q4 2025 Earnings with Positive Outlook
- Significant User Growth: LifeMD ended Q4 2025 with over 322,000 active subscribers, onboarding approximately 1,200 new patients daily and attracting over 120,000 unique daily website visitors, indicating strong momentum in patient acquisition that is expected to drive revenue growth further.
- Strong Financial Performance: The company reported Q4 revenue of $46.9 million, a 4% increase year-over-year, with a gross margin of 87.1% and a net income of $19 million, reflecting significant improvements in cost control and profitability that bolster investor confidence.
- Deepening Strategic Partnerships: The successful launch of oral Wegovy in collaboration with Novo Nordisk positions LifeMD as one of the few virtual care providers fully integrated with major pharmaceutical companies, which is expected to further expand market share and enhance brand influence.
- Optimistic Future Outlook: Management anticipates Q1 2026 revenue in the range of $48 million to $49 million, with a full-year revenue target of $220 million to $230 million, demonstrating confidence in future growth while planning to return to adjusted EBITDA profitability in Q2.
See More
LifeMD Reports Q4 2025 Results Exceeding Expectations
- Strong Earnings Report: LifeMD reported Q4 2025 revenue of $46.9 million, exceeding market expectations by $1.29 million, showcasing the company's robust growth potential in the telehealth sector.
- Improved Profitability: The company achieved a year-over-year gross profit increase of approximately 11%, reaching $40.8 million, reflecting enhanced operational efficiency and cost control capabilities.
- Optimistic Future Outlook: LifeMD projects 2026 revenue between $220 million and $230 million, with a midpoint of $225 million, surpassing the consensus estimate of $222.64 million, indicating strong confidence in future growth.
- Debt-Free Advantage: As of the end of 2025, LifeMD has no debt, providing a solid financial foundation for future expansion and investments, thereby enhancing its competitive position in the market.
See More
LifeMD Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Highlights: LifeMD reported a Q4 GAAP EPS of -$0.04, beating expectations by $0.02, with revenue of $46.9 million reflecting a 3.9% year-over-year increase, surpassing estimates by $1.29 million, indicating robust market performance.
- Future Outlook: The guidance for Q1 2026 projects revenue between $48 million and $49 million, showcasing the company's confidence in future growth, particularly as GLP-1 patient sign-ups have doubled compared to Q4 2025.
- Adjusted EBITDA Expectations: Adjusted EBITDA is expected to return to profitability in Q2 2026 as customer acquisition costs decline, with a significant rise in patient volumes positively impacting the financial results for the latter half of 2026.
- Annual Guidance: For the full year 2026, revenue is projected between $220 million and $230 million, representing a year-over-year growth of 13% to 19%, with annualized run-rate revenue expected to exceed $250 million by Q4 2026, driven by momentum in GLP-1 and women's health sectors.
See More
LifeMD Executives Allegedly Breached Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether LifeMD, Inc. executives breached their fiduciary duties to shareholders, with potential legal risks that could undermine shareholder confidence.
- Overstated Competitive Position: A federal securities lawsuit claims that LifeMD's competitive position was materially overstated, which may distort investor expectations regarding the company's future and impact shareholder investment decisions.
- Improper Financial Guidance: LifeMD's decision to raise its 2025 guidance is criticized as reckless due to the failure to adequately account for rising customer acquisition costs in its RexMD segment, potentially leading to poor future financial performance.
- Lack of Disclosure: The company failed to disclose customer acquisition costs related to the sale of obesity drugs, resulting in materially false and misleading statements about LifeMD's business, operations, and prospects, which could trigger shareholder lawsuits.
See More
